Nucleoside Metabolic Inhibitor class drugs

4 results

  • Inqovi

    (CEDAZURIDINE and DECITABINE)
    Taiho Pharmaceutical Co., Ltd.
    Usage: INQOVI is indicated for treating adult patients with myelodysplastic syndromes (MDS), including both previously treated and untreated forms, as well as chronic myelomonocytic leukemia (CMML), specifically targeting various French-American-British subtypes and patients in intermediate to high-risk groups according to the International Prognostic Scoring System.

  • Lonsurf

    (trifluridine and tipiracil)
    Taiho Pharmaceutical Co., Ltd.
    Usage: LONSURF is indicated for adult patients with metastatic colorectal cancer previously treated with specified chemotherapy regimens and targeted therapies, and for those with metastatic gastric or gastroesophageal junction adenocarcinoma after two prior chemotherapy lines involving fluoropyrimidine and platinum-based treatments.

  • Onureg

    (azacitidine)
    Celgene Corporation
    Usage: ONUREG is indicated for the continued treatment of adults with acute myeloid leukemia who have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are unable to complete intensive curative therapy.

  • Vyxeos

    ((daunorubicin and cytarabine) liposome)
    Jazz Pharmaceuticals, Inc.
    Usage: VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.